We hope you find what you’re looking for. You can email us if you need additional help.
VANCOUVER, BC – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic
Dear Valued Shareholders, This is the news you’ve been waiting for. Optimi Health today announced that it has entered into a $1.2 million CAD definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through pre-clinical research
Yesterday, Optimi Health announced an important MDMA and psilocybin supply agreement for Australians approved under the country’s Authorised Prescribers Scheme. Our new long-term relationship with Mind Medicine Australia positions Optimi as the primary supplier to Australia’s newly regulated psychedelic market.
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
